Allergy Immunotherapy Advances: HDM Market Analysis

DelveInsight’s “TCR Therapy Pipeline Insight 2025” report is your ultimate guide to over 50 companies and 55+ pipeline drugs revolutionizing the TCR Therapy landscape. We’ve got the inside scoop on drug profiles from lab bench to bedside, plus a deep dive into how these therapies stack up by type, stage, delivery method, and molecule class. And don’t forget, we spotlight the inactive ones for a complete picture.

Ready to uncover the hottest drugs and treatment breakthroughs in TCR Therapy? Jump into DelveInsight’s full report now! @ TCR Therapy Pipeline Outlook

Key Takeaways from the TCR Therapy Pipeline Report

• On August 19, 2025, Christian Hinrichs kicked off a groundbreaking study testing a single dose of E7 TCR-T cells as a pre-treatment boost for advanced HPV-linked cancers. The goal? Shrink tumors to make main treatments like chemo-radiation or surgery more effective and boost survival rates.
• On August 12, 2025, BlueSphere Bio Inc. launched a thrilling clinical trial for BSB-1001, a cutting-edge cell therapy targeting blood cancers like AML, ALL, and MDS. It’s all about safety and stopping cancer from coming back.
• DelveInsight’s TCR Therapy Pipeline report reveals an electrifying arena with 50+ active innovators crafting 55+ therapies for TCR Therapy advancements.
• Leading TCR Therapy Companies include Immunocore, Guangdong Xiangxue Precision Medical Technology, Altimmune, Immatics, TScan Therapeutics, SCG Cell Therapy, Treadwell Therapeutics, Adaptimmune, Immatics N.V., and more.
• Exciting TCR Therapy Pipeline Therapies like Fludarabine, Aldesleukin, Blinatumomab, Cyclophosphamide, Tebentafusp, Cisplatin, Gemcitabine, ALT-801, and others are turning heads.

Dive deep into TCR Therapy clinical trials, emerging treatments, and top players with DelveInsight’s expert take @ TCR Therapy Treatment Drugs

TCR Therapy Emerging Drugs Profile

• Brenetafusp: Immunocore
  IMC-F106C is an ImmTAC zeroing in on PRAME for HLA-A02 carriers (about 40% of Western folks). To broaden its reach, the company is rolling out IMC-T119C, a trailblazing ImmTAC for PRAME on HLA-A24 (60% in Japan, 15-20% in the West). It’s in Phase III for first-line advanced cutaneous melanoma.
• Pemvidutide – Altimmune
  Pemvidutide (proposed INN, formerly ALT-801) is a game-changing peptide GLP-1/glucagon dual agonist tackling obesity and NASH. It mimics diet and exercise by curbing appetite (GLP-1) and ramping up energy burn (glucagon). This combo could deliver weight loss like bariatric surgery, plus it breaks down liver fat and fights insulin resistance. With Altimmune’s EuPortTM tech for weekly dosing and better tolerance, Phase I showed massive drops in weight, liver fat, and lipids. Now in Phase II for NASH.
• TSC 101: TScan Therapeutics
  TSC-101 is the pioneer cell therapy hitting minor histocompatibility antigen HA-2 to battle leukemia and prevent post-transplant relapse. This TCR-T therapy from TScan targets HA-2 to wipe out residual disease in AML, MDS, and ALL after HCT. It’s in Phase I for hematologic cancers.

The TCR Therapy Pipeline Report Provides Insights into

• Detailed breakdowns of companies pushing TCR Therapy therapies, with totals per company.
• Segmentation of candidates into early, mid, and late stages for TCR Therapy treatment.
• TCR Therapy Companies diving into targeted therapies, including active and inactive projects.
• TCR Therapy Drugs sorted by phase, route, target, solo or combo, action mechanism, and molecule type.
• Comprehensive analysis of partnerships (biz-to-biz and biz-academia), licensing, and funding to supercharge the TCR Therapy market.

Explore revolutionary therapies and trials in the TCR Therapy Pipeline. Grab DelveInsight’s detailed report today! @ New TCR Therapy Drugs

TCR Therapy Companies
Immunocore, Guangdong Xiangxue Precision Medical Technology, Altimmune, Immatics, TScan Therapeutics, SCG Cell Therapy, Treadwell Therapeutics, Adaptimmune, Immatics N.V., and others.

The TCR Therapy Pipeline report evaluates therapeutics by Route of Administration, grouping them as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Products are classified by Molecule Type, including:

• Monoclonal antibody
• Small molecule
• Peptide

Get the scoop on fresh drugs, pipeline updates, and major players with DelveInsight’s sharp analysis @ TCR Therapy Market Drivers and Barriers

Scope of the TCR Therapy Pipeline Report

• Coverage: Global
• TCR Therapy Companies: Immunocore, Guangdong Xiangxue Precision Medical Technology, Altimmune, Immatics, TScan Therapeutics, SCG Cell Therapy, Treadwell Therapeutics, Adaptimmune, Immatics N.V., and others.
• TCR Therapy Pipeline Therapies: Fludarabine, Aldesleukin, Blinatumomab, Cyclophosphamide, Tebentafusp, Cisplatin, Gemcitabine, ALT-801, and others.
• TCR Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• TCR Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Secure DelveInsight’s in-depth TCR Therapy Pipeline report right away! @ TCR Therapy Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. TCR-Therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. TCR-Therapy – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. IMC F106C: Immunocore
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pemvidutide – Altimmune
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TSC-100: TScan Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. TCR-Therapy Key Companies
18. TCR-Therapy Key Products
19. TCR-Therapy – Unmet Needs
20. TCR-Therapy – Market Drivers and Barriers
21. TCR-Therapy – Future Perspectives and Conclusion
22. TCR-Therapy Analyst Views
23. TCR-Therapy Key Companies
24. Appendix

About Us

DelveInsight is a top-tier healthcare market research and consulting firm, delivering premium intelligence and analysis for savvy decisions. Our life sciences and healthcare experts offer tailored solutions and global insights. Reach out for top-notch, timely data to stay on top.

Contact us

 

Kanishk

 

kkumar@delveinsight.com

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight 2025” report offers detailed analysis on over 75 companies and 80+ pipeline drugs in the Amyotrophic Lateral Sclerosis landscape. It includes profiles of Amyotrophic Lateral Sclerosis pipeline drugs across clinical and nonclinical phases. The report also evaluates therapeutics by product type, development stage, administration route, and molecule type, while highlighting inactive pipeline products.

Dive into our newest discoveries in Amyotrophic Lateral Sclerosis research. Discover our cutting-edge pipeline now! @ Amyotrophic Lateral Sclerosis Pipeline Outlook

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

• On August 20, 2025, Amydis Inc. unveiled a trial to evaluate the safety and tolerability of a single intravenous dose of the investigational retinal tracer AMDX-2011P in individuals with neurodegenerative conditions like Parkinson’s disease and ALS.
• On August 19, 2025, AL-S Pharma initiated a Phase 2a study assessing safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial Amyotrophic Lateral Sclerosis (fALS) and sporadic Amyotrophic Lateral Sclerosis (sALS).
• On August 13, 2025, Amylyx Pharmaceuticals Inc. disclosed a study for ALS patients from the CENTAUR trial (Study AMX3500). In the open-label extension, all received active treatment (AMX0035), with blinding maintained from the initial double-blind phase. The aim was to evaluate long-term safety and efficacy of AMX0035.
• On August 12, 2025, Ionis Pharmaceuticals Inc. launched a trial to assess ION363’s impact on clinical function and survival in carriers fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
• DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report showcases a dynamic field with over 75 active participants developing 80+ therapies for Amyotrophic Lateral Sclerosis management.
• Leading Amyotrophic Lateral Sclerosis Companies include Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Promising Amyotrophic Lateral Sclerosis Pipeline Therapies include Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), RT001, ARGX-119, AMX0035, ION363, ANX005, and others.

Keep up with the latest progress in Amyotrophic Lateral Sclerosis therapies. Access updates and join the advancements in Neurology care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment

Amyotrophic Lateral Sclerosis Emerging Drugs Profile

• MN-166: MediciNova
  MN-166 is a pioneering, orally available small molecule that reduces pro-inflammatory cytokines like IL-1ß, TNF-a, and IL-6, while potentially boosting anti-inflammatory IL-10. It also acts as a toll-like receptor 4 (TLR4) antagonist, aiding in neuroinflammation reduction. The drug is under Phase II/III evaluation for ALS.
• RNS60: Revalesio
  RNS60 aims to modify and possibly reverse neurological disorders. It stimulates intracellular pathways to enhance mitochondrial production and function, and decrease inflammation. RNS60 protects neurons and oligodendrocytes, and adjusts immune cell activity for balance. It has Orphan Drug and Fast Track status for ALS from the US FDA. It’s in Phase II trials for ALS.
• VM202: Helixmith
  VM202 is a groundbreaking gene therapy that promotes tissue repair. Injected along peripheral nerves, it induces HGF production to safeguard nerves, encourage neuron growth, and address atrophy. The US FDA awarded it orphan drug and fast track designations. It’s in Phase II for ALS.
• QRL-201: QurAlis Corporation
  QRL-201 is a novel candidate to restore STMN2 expression in ALS patients. STMN2 is crucial for neural repair and axonal stability, often reduced in ALS cases. QRL-201 addresses STMN2 dysfunction in QurAlis ALS motor neuron models with TDP-43 pathology. It’s in Phase I trials for ALS.

The Amyotrophic Lateral Sclerosis Pipeline report offers insights into:

• Comprehensive details on companies advancing Amyotrophic Lateral Sclerosis therapies, including total therapies per company.
• Segmentation of therapeutic candidates into early, mid, and late stages for Amyotrophic Lateral Sclerosis treatment.
• Amyotrophic Lateral Sclerosis Companies engaged in targeted therapies, with active and inactive projects.
• Amyotrophic Lateral Sclerosis Drugs categorized by phase, route, target, monotherapy or combination, mechanism, and molecule type.
• In-depth review of partnerships (corporate and academic), licensing, and funding to drive Amyotrophic Lateral Sclerosis market growth.

Explore opportunities in Amyotrophic Lateral Sclerosis drugs through our innovative research initiatives @ Amyotrophic Lateral Sclerosis Unmet Needs

Amyotrophic Lateral Sclerosis Companies
Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.

The Amyotrophic Lateral Sclerosis pipeline report evaluates therapeutics by Route of Administration, grouping them as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Products are classified by Molecule Type, including:

• Monoclonal antibody
• Small molecule
• Peptide

Check out the newest developments in Amyotrophic Lateral Sclerosis treatment on our site. Learn how we’re shaping neurology’s future @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report

• Coverage: Global
• Amyotrophic Lateral Sclerosis Companies: Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
• Amyotrophic Lateral Sclerosis Pipeline Therapies: Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), RT001, ARGX-119, AMX0035, ION363, ANX005, and others.
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a comprehensive look at our research and upcoming strategies, review the complete Amyotrophic Lateral Sclerosis Pipeline details @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MN-166: MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. QRL-201: QurAlis Corporation
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Amyotrophic Lateral Sclerosis Key Companies
21. Amyotrophic Lateral Sclerosis Key Products
22. Amyotrophic Lateral Sclerosis – Unmet Needs
23. Amyotrophic Lateral Sclerosis – Market Drivers and Barriers
24. Amyotrophic Lateral Sclerosis – Future Perspectives and Conclusion
25. Amyotrophic Lateral Sclerosis Analyst Views
26. Amyotrophic Lateral Sclerosis Key Companies
27. Appendix

About Us

DelveInsight is a premier healthcare market research and consulting firm, equipping clients with superior intelligence and analysis for strategic decisions. Our experts in life sciences and healthcare provide customized solutions and insights globally. Connect for accurate, up-to-date data to stay ahead.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Diffuse Large B-Cell Lymphoma Pipeline Insights 2025” report, packed with juicy details on over 70 companies and 75+ pipeline drugs shaking up the Diffuse Large B-Cell Lymphoma scene. We’ve got the scoop on drug profiles from early lab stages to advanced clinical trials, plus a deep dive into how these therapies stack up by type, stage, delivery method, and molecule class. Oh, and we spotlight the inactive ones too for the full picture.

Get in on the action with fresh intel! Grab DelveInsight’s full Diffuse Large B-Cell Lymphoma Pipeline Report to check out hot new therapies, top players, and what’s next for treatments @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report

Cool Highlights from the Diffuse Large B-Cell Lymphoma Pipeline Report

• In August 2025, Genmab kicked off a trial comparing epcoritamab plus lenalidomide (E-Len) against rituximab plus gemcitabine and oxaliplatin (R-GemOx) for adults with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). They’ll track side effects and disease changes closely.
• In August 2025, Merck Sharp & Dohme LLC ran a Phase 2 study pitting Zilovertamab Vedotin (MK-2140) plus R-CHP against Polatuzumab Vedotin plus R-CHP in first-time GCB subtype DLBCL patients.
• DelveInsight’s report shows a buzzing arena with 70+ active teams crafting 75+ therapies for Diffuse Large B-Cell Lymphoma.
• Top Diffuse Large B-Cell Lymphoma Companies include Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and more.
• Standout Diffuse Large B-Cell Lymphoma Therapies like Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others are making waves.

See how Diffuse Large B-Cell Lymphoma care is leveling up. Jump into DelveInsight’s detailed pipeline Analysis for the inside scoop on promising game-changers @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies

Diffuse Large B-Cell Lymphoma Emerging Drugs Profile

• Brentuximab vedotin: Pfizer
  Brentuximab vedotin (Adcetris) is a powerhouse anti-cancer drug. It’s approved for Classical Hodgkin lymphoma after stem cell transplant fails or for those not eligible, plus for high-risk relapse cases post-transplant. It also tackles relapsed systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, CD30+ mycosis fungoides after systemic therapy, relapsed CD30+ cutaneous T-cell lymphoma, and first-line pediatric CD30+ Hodgkin lymphoma. Right now, it’s in Phase III trials for Diffuse Large B Cell Lymphoma.
• THOR-707: Sanofi
  THOR-707 is a smartly engineered IL-2 with PEGylation that dodges toxic receptors, boosting killer T cells and NK cells without the bad side effects. It’s in Phase II for Diffuse Large B Cell Lymphoma.
• Abexinostat: Xynomic Pharmaceuticals
  Abexinostat is a wide-ranging HDAC inhibitor that tweaks histones and proteins for better cancer control. It’s hitting Phase II for Diffuse Large B-cell lymphoma.
• RNK05047: Ranok Therapeutics
  RNK05047 is a novel small-molecule degrader targeting BRD4 in tumors, using Ranok’s CHAMP tech. The Phase I/II CHAMP-1 trial is checking safety, dosing, and early anti-cancer effects.
• BMF-219: Biomea Fusion
  BMF-219 is an oral covalent menin inhibitor blocking key cancer drivers like MLL, NPM1, MYC, HOX, and MEIS1. It’s in Phase I for Diffuse Large B Cell Lymphoma.
• ADI-001: Adicet Bio
  ADI-001 is an off-the-shelf gamma delta CAR T therapy targeting B-cell NHL via CD20 and innate receptors. It got Fast Track from the FDA in 2022. Currently in Phase I for Diffuse Large B Cell Lymphoma.

The Diffuse Large B-Cell Lymphoma pipeline report spills the beans on:

• Deep dives into companies brewing therapies for Diffuse Large B-Cell Lymphoma, with totals per company.
• Breakdowns of candidates by early, mid, and late stages.
• Companies chasing targeted therapies, including active and inactive efforts.
• Drugs sorted by phase, route, target, solo or combo use, action mode, and molecule type.
• Full analysis of partnerships (biz-to-biz and biz-academia), licensing, and funding to fuel the Diffuse Large B-Cell Lymphoma market.

Snag a closer look at the hottest moves in the Diffuse Large B-Cell Lymphoma pipeline. Check out DelveInsight’s pro report now! @ Diffuse Large B-Cell Lymphoma Unmet Needs

Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.

The Diffuse Large B-Cell Lymphoma pipeline report evaluates therapies by Route of Administration, grouping them like:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Products are also sorted by Molecule Type, such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Grab DelveInsight’s fresh report for smart takes on upcoming drug shifts @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report

• Coverage: Global
• Diffuse Large B-Cell Lymphoma Companies: Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
• Diffuse Large B-Cell Lymphoma Therapies: Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
• Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Who’s winning the Diffuse Large B-Cell Lymphoma drug race? Find out with DelveInsight’s exclusive pipeline Report—grab it today! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Diffuse Large B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diffuse Large B-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diffuse Large B-Cell Lymphoma Key Companies
21. Diffuse Large B-Cell Lymphoma Key Products
22. Diffuse Large B-Cell Lymphoma – Unmet Needs
23. Diffuse Large B-Cell Lymphoma – Market Drivers and Barriers
24. Diffuse Large B-Cell Lymphoma – Future Perspectives and Conclusion
25. Diffuse Large B-Cell Lymphoma Analyst Views
26. Diffuse Large B-Cell Lymphoma Key Companies
27. Appendix

About Us

DelveInsight is a top-notch healthcare market research and consulting outfit, arming clients with top-tier intel and analysis for smart decisions. Our pros in life sciences and healthcare deliver tailored solutions and insights worldwide. Link up for premium, current data to lead the pack.

Contact Us

 

Kanishk

 

kkumar@delveinsight.com

DelveInsight’s “ Huntington’s Disease Pipeline Insight 2025 “ report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Huntington’s Disease pipeline landscape. It covers the Huntington’s Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Huntington’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Huntington’s Disease Treatment Drugs @ Huntington’s Disease Pipeline Outlook Report

Key Takeaways from the Huntington’s Disease Pipeline Report

• On 19 September 2025, Azidus Brasil conducted a phase II dose-response study in which participants with HD will receive three intravenous injections of the investigational product or placebo (one every month for three months) a total of three cycles. The subjects will be randomized in 2: 2: 1 ratio for the groups G1: lower dose (1×10^6 cells/weight range), G2: higher dose (2×10^6 cells/weight range), or G3: placebo.
• On 18 September 2025, Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) conducted a study consists of 2 parts: Dose-Finding Part and Expansion Part; each part consists of 3 phases: Screening Phase (8 weeks, with extension to 12 weeks to accommodate scheduling if needed), Treatment and Initial Follow-Up Phase (52 weeks) and Long-Term Follow-Up Phase (4 years). In the Dose-Finding Part, 2 dose titers will be tested in 3-6 subjects in each cohort. Once a dose is selected based on Dose-Limiting Toxicities, an additional 6 subjects will be enrolled into the Dose Expansion Part.
• On 15 September 2025, Supernus Pharmaceuticals Inc. organized a study is to assess the magnitude of the baseline difference between participants with early Huntington’s Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
• DelveInsight’s Huntington’s Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Huntington’s Disease treatment.
• The leading Huntington’s Disease Companies such as Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio, and others.
• Promising Huntington’s Disease Pipeline Therapies such as Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.

Discover groundbreaking developments in Huntington’s Disease therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Huntington’s Disease Clinical Trials Assessment

The Huntington’s Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Huntington’s Disease Pipeline Report also highlights the unmet needs with respect to Huntington’s Disease.

Huntington’s Disease Overview

Huntington’s disease is a genetic, progressive, neurodegenerative disorder characterized by the gradual development of involuntary muscle movements affecting the hands, feet, face, and trunk and progressive deterioration of cognitive processes and memory (dementia). This disease causes changes in the central area of the brain, which affect movement, mood and thinking skills. Symptoms of Huntington’s disease usually develop between ages 30 and 50, but they can appear as early as age 2 or as late as 80.

Huntington’s Disease Emerging Drugs Profile

• RG6042: Hoffmann-La Roche

Tominersen (ASO-HTT, RG6042) is an antisense drug in development for the treatment of Huntington’s disease. Tominersen is designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington’s disease. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Huntington’s disease.

• PTC518: PTC Therapeutics

PTC518, a small molecule that can be taken orally, reduces the production of the mutated Huntingtin protein that leads to injury and death of the neuron, which results in disease progression. The orally bioavailable small molecule penetrates the blood brain barrier, is selective, titratable, and not effluxed. Currently the drug is in Phase II stage of its clinical trial for the treatment of Huntington’s disease.

• ALN-HTT02: Alnylam Pharmaceuticals

ALN-HTT02 is an innovative therapeutic approach for Huntington’s disease developed by Alnylam Pharmaceuticals. This drug is a small interfering RNA (siRNA) designed to reduce the production of the huntingtin protein, which is implicated in the disease’s pathology. It works by targeting a specific region of the HTT gene’s messenger RNA (mRNA), promoting its degradation and thereby preventing the synthesis of both normal and mutant huntingtin proteins. Administered via intrathecal injection. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Huntington’s disease.

Stay informed about the Huntington’s Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Huntington’s Disease Unmet Needs

The Huntington’s Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Huntington’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington’s Disease Treatment.
• Huntington’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Huntington’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington’s Disease market

Huntington’s Disease Companies

Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio and others.

Huntington’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Huntington’s Disease Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Transform your understanding of the Huntington’s Disease Pipeline! See the latest progress in drug development and clinical research @ Huntington’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Huntington’s Disease Pipeline Report

• Coverage- Global
• Huntington’s Disease Companies- Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio and others.
• Huntington’s Disease Pipeline Therapies- Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.
• Huntington’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Huntington’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Genetic Disorders Research–Access the Full Huntington’s Disease Pipeline Analysis Today! @ Huntington’s Disease Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Huntington’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Huntington’s Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RG6042: Hoffmann-La Roche
9. Mid Stage Products (Phase II)
10. PTC518: PTC Therapeutics
11. Early Stage Products (Phase I)
12. ALN-HTT02: Alnylam Pharmaceuticals
13. Mid Stage Products (Phase II)
14. Preclinical Stage Products
15. Drug Name: Company Name
16. Inactive Products
17. Huntington’s Disease – Collaborations Assessment- Licensing / Partnering / Funding
18. Huntington’s Disease – Unmet Needs
19. Huntington’s Disease – Market Drivers and Barriers
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s Hemophilia A Pipeline Insight, 2025 report provides comprehensive analysis of 40+ companies and 40+ pipeline drugs shaping the Hemophilia A treatment landscape. The report covers Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also includes a detailed assessment of therapeutics by product type, clinical stage, route of administration, and molecule type, while highlighting inactive pipeline products.

Discover the latest therapies and treatment options in the Hemophilia A pipeline. Access DelveInsight’s full report today! @ Hemophilia A Pipeline Outlook 

Key Takeaways from the Hemophilia A Pipeline Report

• On 10 October 2025, Hoffmann-La Roche initiated a Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NXT007 in patients with severe or moderate Hemophilia A.

• On 08 October 2025, BioMarin Pharmaceutical announced a Phase III study to assess the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe Hemophilia A.

• The Hemophilia A pipeline includes 40+ active companies developing 40+ pipeline therapies for treatment.

• Leading Hemophilia A companies include Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, LLC, CSL Behring, and others.

• Promising Hemophilia A drugs in development include Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.

Explore ongoing Hemophilia A clinical trials and the latest pipeline developments with DelveInsight @ Hemophilia A Treatment Drugs 

Hemophilia A Emerging Drugs Profile

• AGN-193408 – Allergan
  Allergan is conducting a multicenter study to evaluate the safety and efficacy of AGN-193408 SR. The implant delivers preservative-free AGN-193408 in a biodegradable polymer matrix and is under evaluation in dose escalation studies.

• OCTA101 – Octapharma
  OCTA101, a combination of human-cl rhFVIII and recombinant von Willebrand Factor fragment, is being studied in Phase I/II dose escalation trials to assess subcutaneous administration in adults with severe Hemophilia A. Pharmacokinetics, dose proportionality, and protective FVIII:C levels are key endpoints.

• Valoctocogene roxaparvovec – BioMarin Pharmaceutical
  Valoctocogene roxaparvovec is an investigational gene therapy administered as a single infusion. Ongoing trials are evaluating safety, Factor VIII activity levels, factor replacement usage, bleed frequency, and quality of life. Its safety and efficacy remain under clinical investigation.

Hemophilia A Pipeline Report Insights

• Provides detailed insights into companies developing therapies for Hemophilia A.

• Segments therapeutic candidates into early-, mid-, and late-stage development.

• Includes both active and inactive (dormant or discontinued) projects.

• Categorizes drugs by stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.

• Covers collaborations, licensing agreements, and financing trends driving future market growth.

Hemophilia A Companies

Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, LLC, CSL Behring, and others.

Route of Administration (ROA) Assessment

• Oral

• Intravenous

• Subcutaneous

Molecule Type Assessment

• Small molecules

• Gene therapies

• Bispecific antibodies

• Recombinant proteins

• Fusion proteins

• Coagulants

• Blood coagulation factor replacements

Scope of the Hemophilia A Pipeline Report

• Coverage: Global

• Key Companies: Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, LLC, CSL Behring, and others.

• Pipeline Therapies: Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.

• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Clinical Stage Assessment: Discovery, Preclinical, Phase I–III

Stay informed about the latest Hemophilia A drugs, pipeline developments, and clinical trials with DelveInsight’s expert analysis @ Hemophilia A Companies, Key Products, and Unmet Needs 

Table of Contents

1. Introduction

2. Executive Summary

3. Hemophilia A: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hemophilia A: Analytical Perspective

7. In-depth Commercial Assessment

8. Hemophilia A Collaboration Deals

9. Late Stage Products (Pre-registration)

10. Valoctocogene roxaparvovec – BioMarin Pharmaceutical

11. Late Stage Products (Phase III)

12. Giroctocogene fitelparvovec – Pfizer/Sangamo Therapeutics

13. Mid Stage Products (Phase II)

14. Comparative Analysis

15. NNC0365-3769 A (Mim8) – Novo Nordisk A/S

16. Early Stage Products (Phase I/II)

17. Comparative Analysis

18. BAX 888 – Baxalta/Shire

19. BAY2599023 – Bayer/Ultragenyx

20. Early Stage Products (Phase I)

21. Gene Therapy – Expression Therapeutics, LLC

22. Hemophilia A Key Companies

23. Hemophilia A Key Products

24. Hemophilia A Unmet Needs

25. Hemophilia A Market Drivers and Barriers

26. Hemophilia A Future Perspectives and Conclusion

27. Hemophilia A Analyst Views

28. Hemophilia A Key Companies

29. Appendix

About DelveInsight

DelveInsight is a healthcare-focused market research and consulting firm providing high-quality market intelligence and analysis to support informed business decisions. With a team of industry experts and deep understanding of the life sciences sector, DelveInsight delivers accurate, timely, and actionable insights for clients worldwide.

Contact

Kanishk

kkumar@delveinsight.com

DelveInsight’s Sleep Apnea Pipeline Insight, 2025 report provides a detailed analysis of the current and emerging therapies in the Sleep Apnea treatment landscape. The report covers 20+ companies and 25+ pipeline drugs, spanning clinical and nonclinical stages. It offers a comprehensive assessment of the Sleep Apnea pipeline by product type, clinical stage, route of administration, and molecule type, along with inactive products and market trends.

Discover the latest developments in Sleep Apnea therapies and ongoing clinical trials in our Sleep Apnea Pipeline Outlook Report.

Key Takeaways from the Sleep Apnea Pipeline Report

• On 18 September 2025, Inspire Medical Systems Inc. announced a study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.
• Leading Sleep Apnea companies include Apnime , Incannex Healthcare , Fujian Shengdi Pharmaceutical , Eli Lilly and Company , RespireRx Phamaceuticals , Neurim Pharmaceuticals, and others.
• Promising Sleep Apnea Therapies development include Sivopixant, Acetazolamide, SAS0421a, VI-0521, Zonisamide, Sulthiame, AD128, Mannitol, BAY2586116 and others.

Explore full pipeline insights and see which companies are advancing the most in Sleep Apnea clinical trials in our detailed Sleep Apnea Clinical Trials Assessment.

Sleep Apnea Overview and Epidemiology

Sleep Apnea is a chronic disorder characterized by repeated interruptions in breathing during sleep. It can lead to daytime fatigue, cardiovascular complications, and metabolic disorders. The disorder is broadly classified into obstructive Sleep Apnea (OSA) and central Sleep Apnea (CSA). Prevalence is increasing worldwide, with Sleep Apnea epidemiology studies estimating that 9–38% of adults are affected, with higher rates in males and individuals with obesity. Early diagnosis and effective treatment are crucial to reducing comorbidities and improving quality of life.

Emerging Therapies in the Sleep Apnea Pipeline

• Next-Generation Positive Airway Pressure (PAP) Devices – ResMed Advanced PAP devices aim to improve patient adherence and comfort while maintaining efficacy in airway stabilization. Currently in Phase III clinical trials.
• Oral Pharmacotherapy – Apnimed A novel drug targeting upper airway muscle tone to reduce airway collapse in moderate-to-severe Sleep Apnea. Currently in Phase II development.
• Implantable Neurostimulation Devices – Inspire Medical Systems Devices stimulating the hypoglossal nerve to prevent airway obstruction. Currently in late-stage development.

Sleep Apnea Pipeline Report Highlights

• Detailed insights on Sleep Apnea companies and their active and inactive therapeutic projects.
• Assessment of pipeline drugs and devices by clinical stage: early-stage, mid-stage, and late-stage.
• Categorization by route of administration: oral, implantable, and device-based therapies.
• Molecule types include small molecules, biologics, and combination therapies.
• Analysis of collaborations, licensing agreements, and market financing for future growth of the Sleep Apnea market.

Scope of the Sleep Apnea Pipeline Report

• Coverage: Global
• Key Companies: Apnime , Incannex Healthcare , Fujian Shengdi Pharmaceutical , Eli Lilly and Company , RespireRx Phamaceuticals , Neurim Pharmaceuticals, and others.
• Therapies: Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.
• Assessment by product type (mono, combination) and clinical stage (discovery, preclinical, Phase I–III)

 

Table of Contents

1. Introduction
2. Executive Summary
3. Sleep Apnea: Overview and Epidemiology
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sleep Apnea: Analytical Perspective
7. Late Stage Products (Preregistration)
8. Next-Generation PAP Devices – ResMed
9. Detailed Drug and Device Profiles
10. Mid Stage Products (Phase II)
11. Oral Pharmacotherapy – Apnimed
12. Detailed Drug Profiles
13. Early Stage Products (Phase I)
14. Implantable Devices – Inspire Medical Systems
15. Detailed Device Profiles
16. Preclinical and Discovery Stage Products
17. Detailed Profiles
18. Inactive Products
19. Key Companies
20. Key Products
21. Unmet Needs
22. Market Drivers and Barriers
23. Future Perspectives
24. Analyst Views
25. Appendix

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm offering high-quality insights and market intelligence. With expertise in life sciences and healthcare, DelveInsight provides accurate and real-time intelligence to support informed business decisions and strategic growth.

Contact

Kanishk

kkumar@delveinsight.com

DelveInsight’s Food Allergy Pipeline Insight, 2025 report delivers an in-depth analysis of 25+ companies and 30+ pipeline drugs shaping the Food Allergy treatment landscape. The report covers Food Allergy pipeline drug profiles across clinical and nonclinical stages, with a comprehensive assessment by product type, clinical stage, route of administration, and molecule type. It also highlights inactive pipeline products and provides actionable insights for strategic planning.

Curious about the latest developments in Food Allergy therapies? Explore the emerging treatments and ongoing trials in our Food Allergy Pipeline Outlook Report.

Key Takeaways from the Food Allergy Pipeline Report

• On 08 October 2025, DBV Technologies initiated a Phase 3 randomized double-blind, placebo-controlled study of 6 months to assess the safety of DBV712 250 mcg in children aged 1–3 years with peanut allergy. Participants completing the 6-month DBPC period will have the option to enter an 18-month open-label extension.
• On 01 October 2025, ALK-Abelló A/S announced a Phase I/II, dose-escalation, multi-site trial for subjects with peanut allergy confirmed via double-blind, placebo-controlled food challenge. The trial is conducted in three parts: determining entry doses, evaluating tolerability across age groups, and assessing efficacy of two maintenance doses of the SLIT tablet in adolescents and children.
• The Food Allergy pipeline remains robust, with 25+ active players developing 30+ pipeline therapies for treatment.
• Leading Food Allergy companies include DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, and others.
• Promising Food Allergy drugs in development include Ligelizumab 120 mg, Dupilumab, and Omalizumab, among others.

 

Food Allergy Overview

Food allergies are adverse immune responses triggered reproducibly by specific foods. Reactions can range from mild to life-threatening, affecting the skin, gastrointestinal tract, respiratory system, and cardiovascular system. Unlike food intolerances, food allergies involve the immune system. Prevalence is rising, particularly in developed countries, with approximately 5–8% of children and 1–2% of adults affected worldwide.

Emerging Drugs in the Food Allergy Pipeline

• Viaskin Peanut (DBV712) – DBV Technologies Viaskin Peanut is an epicutaneous immunotherapy (EPIT) patch delivering allergens to the immune system through intact skin. It creates a condensation chamber to solubilize the allergen, stimulating immune tolerance. Currently in the Registration stage for peanut allergy treatment.
• PVX-108 – Aravax PVX-108 is a next-generation, allergen-specific immunotherapy using peptides to target T cells driving peanut allergy. Administered once per month, it aims to induce tolerance safely without the anaphylaxis risk associated with whole-peanut therapies. Currently in Phase II clinical development.
• INT301 – Intrommune Therapeutics INT301 is an oral mucosal immunotherapy delivered via a toothpaste-based formulation. It targets immune tolerance in peanut allergy with improved safety and convenience compared to traditional oral immunotherapy. Currently in Phase I development.

Food Allergy Pipeline Report Highlights

• Detailed insights on Food Allergy companies and their therapeutic pipelines.
• Segmentation of therapies by clinical stage: early-stage, mid-stage, and late-stage.
• Analysis of active and inactive projects and targeted therapeutics.
• Food Allergy drugs categorized by route of administration: intravenous, subcutaneous, oral, and intramuscular.
• Molecule types include monoclonal antibodies, small molecules, and peptides.
• Collaboration, licensing, and financing strategies to advance the Food Allergy market.

Scope of the Food Allergy Pipeline Report

• Coverage: Global
• Key Companies: DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, and others.
• Therapies: Ligelizumab 120 mg, Dupilumab, Omalizumab, and more.
• Assessment by product type (mono, combination, mono/combination) and clinical stage (discovery, preclinical, Phase I–III).

 

Table of Contents

1. Introduction
2. Executive Summary
3. Food Allergy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Food Allergy: Analytical Perspective
7. Late Stage Products (Preregistration)
8. Viaskin Peanut: DBV Technologies
9. Detailed Drug Profiles
10. Mid Stage Products (Phase II)
11. PVX-108: Aravax
12. Detailed Drug Profiles
13. Early Stage Products (Phase I)
14. INT301: Intrommune Therapeutics
15. Detailed Drug Profiles
16. Preclinical and Discovery Stage Products
17. Detailed Drug Profiles
18. Inactive Products
19. Key Companies
20. Key Products
21. Unmet Needs
22. Market Drivers and Barriers
23. Future Perspectives
24. Analyst Views
25. Appendix

About DelveInsight

DelveInsight is a healthcare-focused market research and consulting firm offering high-quality market intelligence and insights to support informed business decisions. With expertise in life sciences and healthcare, DelveInsight delivers accurate and timely intelligence for clients worldwide.

Contact

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Cushing Syndrome Pipeline Insight 2025” delivers a comprehensive analysis of the emerging therapeutic landscape for Cushing syndrome, encompassing insights on 4+ leading biotechnology and pharmaceutical companies advancing 4+ innovative pipeline therapies. The report provides detailed evaluation of clinical and preclinical-stage products, therapeutic categorization by development phase, administration routes, and molecular mechanisms. Additionally, it identifies inactive pipeline candidates and highlights critical unmet medical needs in this rare endocrine disorder space.

Key Pipeline Update: 

On September 30, 2025, Corcept Therapeutics initiated a long-term safety evaluation study assessing relacorilant in Cushing syndrome patients who previously demonstrated successful response to this investigational therapy, representing continued advancement of this promising clinical candidate.

Cushing Syndrome Disease Overview

Cushing syndrome, clinically characterized as hypercortisolism, represents a rare but serious hormonal disorder resulting from prolonged exposure to elevated cortisol levels. The condition manifests through two primary etiological categories: adrenocorticotropic hormone (ACTH)-dependent presentations, typically caused by pituitary adenomas producing excessive ACTH, and ACTH-independent forms originating from adrenal pathology. The disease predominantly affects adult populations aged 20-50 years, with pituitary-dependent Cushing disease (also called Cushing’s disease) being the most common variant. Pathologically, excessive ACTH production overwhelms normal hypothalamic-pituitary-adrenal axis feedback regulation, resulting in uncontrolled adrenal cortisol secretion. The chronic systemic elevation of cortisol precipitates substantial clinical morbidity through metabolic complications, cardiovascular disease, immunosuppression, psychological disturbances, and reduced quality of life. Prolonged cortisol excess significantly increases mortality risk and impairs functional capacity, establishing urgent treatment needs for disease-modifying interventions.

Leading Cushing Syndrome Companies and Development Pipeline

The therapeutic development landscape comprises innovative companies advancing diverse mechanistic approaches:

Corcept Therapeutics – Developing relacorilant (CORT125134), a selective glucocorticoid receptor II antagonist receiving orphan drug designations in the United States and European Union for Cushing syndrome management.

Cortendo AB – Advancing endocrine-focused therapies for cortisol excess disorders through novel therapeutic platforms.

Crinetics Pharmaceuticals – Pursuing somatostatin receptor-targeted approaches for ACTH-secreting neuroendocrine tumors underlying Cushing pathophysiology.

Recordati Group – Contributing established endocrine expertise and resources to Cushing syndrome therapeutic development.

HRA Pharma – Developing targeted endocrine interventions for rare hormone-related disorders including Cushing syndrome.

Novartis Pharmaceuticals – Leveraging pharmaceutical expertise in endocrine disease management and rare disorder treatment.

Sparrow Pharmaceuticals – Advancing innovative therapeutic candidates for endocrine and metabolic disorders.

 Explore the Complete Cushing Syndrome Pipeline Report

https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Cushing Syndrome Pipeline Therapeutics

Late-Stage Development (Phase III)

Relacorilant (CORT125134) – A non-steroidal, selective glucocorticoid receptor II antagonist competitively binding and blocking glucocorticoid receptors. Upon administration, relacorilant prevents ligand-receptor complex translocation to the nucleus and suppresses glucocorticoid receptor-associated gene expression. This mechanism directly antagonizes cortisol effects at the receptor level, providing novel disease-modifying potential. Corcept is investigating relacorilant across multiple serious disorders including Cushing syndrome, adrenal carcinoma, pancreatic cancer, and ovarian malignancies.

Mid-Stage Development (Phase II)

SOM230 LAR 30 mg – Extended-release somatostatin analog targeting ACTH-secreting pituitary adenomas through somatostatin receptor agonism and ACTH suppression.

Pasireotide LAR – Long-acting somatostatin receptor ligand demonstrating efficacy in ACTH-dependent disease through pituitary ACTH inhibition.

Osilodrostat – 11β-hydroxylase inhibitor blocking cortisol synthesis at the adrenal enzyme level, preventing final cortisol production step.

SPI-62 – Investigational therapeutic targeting adrenocorticotropic hormone and cortisol axis dysregulation.

Early-Stage Development (Phase I)

Mifepristone – Glucocorticoid receptor antagonist and progesterone receptor modifier providing peripheral cortisol effect blockade.

Levoketoconazole – Selective 11β-hydroxylase inhibitor reducing cortisol biosynthesis with improved pharmacological profile compared to earlier generation inhibitors.

Preclinical and Discovery Stage

Multiple investigational candidates in preclinical development targeting novel endocrine and metabolic pathways implicated in Cushing pathophysiology.

Therapeutic Assessment Framework

The Cushing Syndrome Pipeline report categorizes therapeutic candidates across multiple evaluation dimensions:

By Development Stage: Discovery, preclinical, Phase I, Phase II, Phase III assessments enabling progression tracking and clinical readiness evaluation.

By Route of Administration: Categorization encompasses oral formulations enabling outpatient use, intravenous administration for acute management, subcutaneous injection for depot formulations, parenteral delivery, and topical preparations where applicable.

By Molecular Type: Classification includes small molecule glucocorticoid antagonists, recombinant fusion proteins, monoclonal antibodies, peptide therapeutics, polymer-based delivery systems, and gene therapy approaches.

By Therapeutic Approach: Mono-therapy vs. combination therapy strategies, reflecting evolving treatment paradigms incorporating multiple complementary mechanisms for enhanced clinical outcomes.

Pipeline Dynamics and Strategic Collaborations

The report provides detailed analysis of company-to-company partnerships, academic-industry collaborations, licensing agreements, and financing mechanisms supporting continued therapeutic development. These strategic relationships accelerate research timelines, facilitate resource sharing, and enhance commercial viability of emerging Cushing syndrome therapeutics.

Report Scope and Coverage

Geographic Coverage: Global therapeutic landscape across all major pharmaceutical markets

Company Portfolio: Comprehensive assessment of therapeutic strategies employed by Corcept Therapeutics, Cortendo AB, Crinetics Pharmaceuticals, Recordati Group, HRA Pharma, Novartis Pharmaceuticals, Sparrow Pharmaceuticals, and additional emerging biotechnology firms

Therapeutic Candidates: Detailed profiles of SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, Relacorilant, and additional investigational agents

Report Table of Contents

• Executive Summary and Key Takeaways
• Cushing Syndrome Disease Pathophysiology and Clinical Overview
• Epidemiology and Patient Population Analysis
• Pipeline Therapeutic Landscape and Development Status
• Late-Stage Products and Clinical Assessment
• Mid-Stage Products and Development Progress
• Early-Stage Candidates and Emerging Approaches
• Preclinical and Discovery Stage Initiatives
• Inactive and Discontinued Pipeline Projects
• Leading Cushing Syndrome Companies and Organizational Profiles
• Key Pipeline Therapeutics and Drug Profiles
• Unmet Medical Needs and Therapeutic Gaps
• Market Drivers, Barriers, and Market Dynamics
• Future Perspectives and Market Evolution
• Strategic Collaborations, Licensing, and Financing
• Analyst Perspectives and Market Insights
• Appendix and Additional Resources

Key Pipeline Insights

Robust Pipeline Development: The Cushing Syndrome Pipeline encompasses 4+ active companies developing 4+ advanced therapeutic candidates across multiple development stages, representing meaningful therapeutic progress in this rare disease space.

Diverse Mechanistic Approaches: Therapies target complementary pathophysiological pathways including glucocorticoid receptor antagonism, ACTH suppression via somatostatin signaling, adrenal cortisol synthesis inhibition, and peripheral cortisol effect blockade.

Unmet Medical Needs: Substantial therapeutic gaps remain including improved tolerability compared to existing treatments, convenient oral formulations, disease-modifying approaches providing long-term remission, and management of resistant disease presentations.

Market Drivers and Barriers: Growing disease recognition, increased diagnostic capability, limited existing treatment options, and potential commercial opportunity drive development. Barriers include small patient populations affecting commercial viability, regulatory complexity for rare disease therapeutics, and development costs relative to addressable market size.

Future Perspectives

The Cushing Syndrome therapeutic landscape is positioned for meaningful transformation through continued innovation in endocrine pathways, mechanism refinement enabling improved efficacy and safety, and expanded patient access to disease-modifying therapies. Success depends on demonstrating superior clinical outcomes, establishing convenient and well-tolerated treatment paradigms, and achieving healthcare system integration for broad patient benefit.

Schedule Expert Consultation on Cushing Syndrome Market Dynamics